IOVA RSI Chart
Last 7 days
4.6%
Last 30 days
1.9%
Last 90 days
46.7%
Trailing 12 Months
76.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 1.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 15, 2024 | bilinsky igor | acquired | - | - | 2,812 | chief operating officer |
Apr 15, 2024 | graf finckenstein friedrich | acquired | - | - | 2,812 | chief medical officer |
Apr 15, 2024 | graf finckenstein friedrich | sold (taxes) | -16,967 | 11.89 | -1,427 | chief medical officer |
Apr 15, 2024 | vogt frederick g | sold (taxes) | -105,238 | 11.89 | -8,851 | interim ceo & general counsel |
Apr 15, 2024 | vogt frederick g | acquired | - | - | 20,834 | interim ceo & general counsel |
Apr 15, 2024 | bilinsky igor | sold (taxes) | -16,967 | 11.89 | -1,427 | chief operating officer |
Mar 04, 2024 | bilinsky igor | sold (taxes) | -123,588 | 16.96 | -7,287 | chief operating officer |
Mar 04, 2024 | vogt frederick g | acquired | - | - | 41,662 | interim ceo & general counsel |
Mar 04, 2024 | vogt frederick g | sold (taxes) | -194,175 | 16.96 | -11,449 | interim ceo & general counsel |
Mar 04, 2024 | graf finckenstein friedrich | sold (taxes) | -136,579 | 16.96 | -8,053 | chief medical officer |
Which funds bought or sold IOVA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 08, 2024 | US BANCORP \DE\ | added | 113 | 347,701 | 467,675 | -% |
May 08, 2024 | Russell Investments Group, Ltd. | reduced | -89.61 | -52,950 | 12,374 | -% |
May 08, 2024 | PROFUND ADVISORS LLC | reduced | -53.74 | -257,830 | 1,387,890 | 0.05% |
May 08, 2024 | Sandy Spring Bank | new | - | 11,856 | 11,856 | -% |
May 08, 2024 | ProShare Advisors LLC | added | 14.53 | 480,338 | 921,952 | -% |
May 08, 2024 | TD Asset Management Inc | added | 96.25 | 5,395,070 | 7,488,220 | 0.01% |
May 08, 2024 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | reduced | -26.19 | -236,937 | 295,180 | -% |
May 08, 2024 | KBC Group NV | reduced | -4.33 | 28,000 | 65,000 | -% |
May 08, 2024 | GREAT LAKES ADVISORS, LLC | reduced | -5.29 | 804,375 | 1,911,540 | 0.02% |
May 08, 2024 | ROANOKE ASSET MANAGEMENT CORP/ NY | reduced | -1.9 | 264,000 | 598,000 | 0.20% |
Unveiling Iovance Biotherapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Iovance Biotherapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 47.0B | 6.8B | -7.88 | 6.87 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.2B | 2.0B | -57.69 | 9.56 | ||||
BMRN | 15.5B | 2.5B | 75.54 | 6.28 | ||||
INCY | 12.0B | 3.8B | 16.12 | 3.19 | ||||
MID-CAP | ||||||||
BBIO | 5.4B | 107.9M | -9.84 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.38 | 9.86 | ||||
AXSM | 3.5B | 251.0M | -11.8 | 13.94 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 28.42 | 4.5 | ||||
NVAX | 627.0M | 983.7M | -1.15 | 0.64 | ||||
CRBP | 467.5M | 881.7K | -13.85 | 481.06 | ||||
INO | 260.8M | 4.9M | -1.93 | 53.59 | ||||
IBIO | 6.4M | 2.1M | -0.24 | 2.14 |
Iovance Biotherapeutics Inc News
Income Statement (Quarterly) | |||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 |
Revenue | 20.8% | 715,000 | 592,000 | 469,000 | 238,000 |
Cost Of Revenue | - | 7,261,000 | - | 4,340,000 | 2,050,000 |
Costs and Expenses | -2.7% | 118,437,000 | 121,738,000 | 118,830,000 | 110,324,000 |
S&GA Expenses | -100.0% | - | 29,903,000 | 26,964,000 | 21,927,000 |
R&D Expenses | -8.8% | 79,783,000 | 87,470,000 | 87,526,000 | 86,347,000 |
EBITDA Margin | -1.6% | -372 | -366 | - | - |
Income Taxes | 19.9% | -1,400,000 | -1,747,500 | -1,243,000 | -500,000 |
Earnings Before Taxes | 3.2% | -114,384,000 | -118,138,000 | -115,003,000 | -107,005,000 |
EBT Margin | -1.6% | -382 | -376 | - | - |
Net Income | 2.9% | -113,000,000 | -116,379,000 | -113,760,000 | -106,528,000 |
Net Income Margin | -1.3% | -378 | -373 | - | - |
Free Cashflow | -44.5% | -126,450,000 | -87,499,000 | -87,660,000 | -103,487,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 11.5% | 870 | 780 | 852 | 757 | 825 | 664 | 546 | 611 | 701 | 777 | 829 | 853 | 751 | 768 | 782 | 818 | 288 | 345 | 396 | 436 | 462 |
Current Assets | 25.2% | 386 | 308 | 383 | 275 | 638 | 479 | 370 | 432 | 490 | 508 | 583 | 667 | 605 | 636 | 724 | 783 | 256 | 316 | 367 | 411 | 445 |
Cash Equivalents | 22.4% | 141 | 115 | 268 | 230 | 543 | 232 | 118 | 108 | 92.00 | 78.00 | 59.00 | 83.00 | 132 | 73.00 | 68.00 | 161 | 53.00 | 19.00 | 39.00 | 77.00 | 54.00 |
Inventory | 69.9% | 18.00 | 10.00 | 9.00 | 10.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -2.0% | 112 | 114 | 113 | 113 | 110 | 105 | 101 | 101 | 103 | 101 | 88.00 | 80.00 | 73.00 | 59.00 | 39.00 | 19.00 | 14.00 | 9.00 | 6.00 | 4.00 | 4.00 |
Liabilities | -3.0% | 190 | 196 | 178 | 179 | 158 | 164 | 152 | 138 | 149 | 156 | 130 | 108 | 103 | 112 | 70.00 | 59.00 | 45.00 | 46.00 | 41.00 | 39.00 | 27.00 |
Current Liabilities | -24.6% | 83.00 | 110 | 91.00 | 89.00 | 87.00 | 91.00 | 79.00 | 64.00 | 77.00 | 89.00 | 65.00 | 61.00 | 55.00 | 55.00 | 64.00 | 55.00 | 40.00 | 39.00 | 35.00 | 34.00 | 22.00 |
Shareholder's Equity | 16.3% | 680 | 585 | 674 | 579 | 667 | 500 | 394 | 473 | 552 | 622 | 698 | 744 | 647 | 656 | 712 | 758 | 243 | 299 | 355 | 397 | 435 |
Retained Earnings | -5.6% | -2,125 | -2,012 | -1,896 | -1,782 | -1,675 | -1,568 | -1,463 | -1,363 | -1,264 | -1,172 | -1,073 | -986 | -905 | -830 | -761 | -703 | -640 | -570 | -507 | -457 | -410 |
Additional Paid-In Capital | 8.1% | 2,805 | 2,594 | 2,579 | 2,360 | 2,343 | 2,069 | 1,859 | 1,839 | 1,818 | 1,795 | 1,771 | 1,731 | 1,553 | 1,487 | 1,473 | 1,461 | 883 | 869 | 0.00 | 0.00 | 845 |
Accumulated Depreciation | 10.7% | 31.00 | 28.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | 9.2% | 280 | 256 | 256 | 225 | 224 | 188 | 158 | 157 | 157 | 157 | 156 | 151 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 1,400 | - | - | - | 1,600 | - | - | - | 3,800 | - | - | - | 3,700 | - | - | - | 2,900 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -45.6% | -122,279 | -83,970 | -84,083 | -93,967 | -99,800 | -77,671 | -63,649 | -77,635 | -73,802 | -53,849 | -57,693 | -54,008 | -62,391 | -62,692 | -40,515 | -36,635 | -65,292 | -53,822 | -42,182 | -33,795 | -29,090 |
Share Based Compensation | 19.3% | 17,178 | 14,399 | 15,821 | 16,740 | 15,665 | 19,509 | 19,780 | 22,468 | 22,265 | 19,104 | 19,306 | 14,414 | 16,941 | 10,232 | 10,706 | 10,537 | 9,412 | 5,407 | 6,598 | 6,426 | 5,846 |
Cashflow From Investing | -53.1% | -111,506 | -72,845 | -79,014 | -156,779 | 153,396 | 461 | 73,715 | 95,763 | 86,516 | 69,338 | 12,748 | -159,165 | 77,211 | 58,753 | -52,955 | -423,756 | 100,105 | 26,814 | 3,495 | 58,683 | 1,033 |
Cashflow From Financing | 20022.2% | 193,576 | 962 | 202,800 | 1,025 | 258,172 | 190,575 | 225 | -2,067 | 1,417 | 4,150 | 20,772 | 163,982 | 50,364 | 2,958 | 1,166 | 568,465 | 3,833 | 2,088 | 664 | 3,381 | -2.00 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Consolidated Statements of Operations | |||
Total revenue | $ 1,189 | ||
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | us-gaap:ProductMember | ||
Costs and expenses | |||
Cost of sales | $ 10,755 | ||
Research and development | 344,077 | $ 294,781 | $ 259,039 |
Selling, general and administrative | 106,916 | 104,097 | 83,664 |
Total costs and expenses | 461,748 | 398,878 | 342,703 |
Loss from operations | (460,559) | (398,878) | (342,703) |
Other income | |||
Interest income, net | 13,043 | 2,985 | 451 |
Net Loss before income taxes | (447,516) | (395,893) | (342,252) |
Income tax benefit | 3,479 | 0 | 0 |
Net Loss | $ (444,037) | $ (395,893) | $ (342,252) |
Net Loss Per Share of Common Stock, Basic | $ (1.89) | $ (2.49) | $ (2.23) |
Net Loss Per Share of Common Stock, Diluted | $ (1.89) | $ (2.49) | $ (2.23) |
Weighted Average Shares of Common Stock Outstanding, Basic | 235,131 | 159,259 | 153,406 |
Weighted Average Shares of Common Stock Outstanding, Diluted | 235,131 | 159,259 | 153,406 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 114,888 | $ 231,731 |
Trade accounts receivable | 151 | |
Short-term investments | 164,979 | 240,114 |
Inventory | 10,372 | |
Prepaid expenses and other assets | 17,458 | 7,271 |
Total Current Assets | 307,848 | 479,116 |
Property and equipment, net | 114,030 | 105,232 |
Intangible assets, net | 229,258 | |
Operating lease right-of-use assets | 62,515 | 73,015 |
Restricted cash | 66,430 | 6,430 |
Long-term assets | 270 | 189 |
Total Assets | 780,351 | 663,982 |
Current Liabilities | ||
Accounts payable | 33,123 | 26,603 |
Accrued expenses | 69,406 | 52,295 |
Operating lease liabilities | 7,777 | 12,587 |
Total Current Liabilities | 110,306 | 91,485 |
Non-Current Liabilities | ||
Operating lease liabilities - non-current | 67,085 | 71,859 |
Deferred tax liabilities | 17,347 | |
Long-term note payable | 1,000 | 1,000 |
Total Non-Current Liabilities | 85,432 | 72,859 |
Total Liabilities | 195,738 | 164,344 |
Commitments and contingencies | ||
Stockholders' Equity | ||
Common stock, $0.000041666 par value; 500,000,000, and 300,000,000 shares authorized, 256,135,715 and 187,812,072 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 11 | 8 |
Accumulated other comprehensive income (loss) | 2,526 | (902) |
Additional paid-in capital | 2,594,448 | 2,068,867 |
Accumulated deficit | (2,012,375) | (1,568,338) |
Total Stockholders' Equity | 584,613 | 499,638 |
Total Liabilities and Stockholders' Equity | 780,351 | 663,982 |
Series A Convertible Preferred Stock | ||
Stockholders' Equity | ||
Preferred stock, Value | 0 | 0 |
Series B Convertible Preferred Stock | ||
Stockholders' Equity | ||
Preferred stock, Value | $ 3 | $ 3 |